NCT00614393View on ClinicalTrials.gov

Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)

PHASE2CompletedINTERVENTIONAL

Enrollment

558

Participants

Timeline

Start Date

December 24, 2007

Primary Completion Date

June 1, 2010

Study Completion Date

March 7, 2012

Conditions

Metastatic Colorectal Cancer

Interventions

BIOLOGICAL

dalotuzumab

IV infusion

DRUG

irinotecan hydrochloride

IV infusion

BIOLOGICAL

cetuximab

IV infusion

DRUG

placebo

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00614393 - Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004) | Biotech Hunter | Biotech Hunter